Dr. Jessica Meznarich

Pediatric Hematology Oncology
100 North Mario Capecchi Drive, Suite 1400, 
Salt Lake City, UT 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
16 Years of Experience
100 North Mario Capecchi Drive, Suite 1400, 
Salt Lake City, UT 
OverviewInsuranceLocationsClinical Research

Overview

Jessica Meznarich is a Pediatric Hematologist Oncology provider in Salt Lake City, Utah. Dr. Meznarich has been practicing medicine for over 16 years and is rated as an Experienced provider by MediFind in the treatment of Infantile Pyloric Stenosis. Her top areas of expertise are Dyserythropoietic Anemia and Thrombocytopenia, Anemia, Pure Red Cell Aplasia, and Aase Syndrome. Dr. Meznarich is currently accepting new patients.

Her clinical research consists of co-authoring 22 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Washington School Of Medicine, 2010
Residency
Primary Children's Hospital
Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in WA
Board Certifications
American Board Of Pediatrics
American Board Of Pediatrics
Fellowships
University of Utah Medical Center
Hospital Affiliations
Primary Children's Hospital
St George Regional Hospital
Languages Spoken
English
Mandarin
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Primary Children's Hospital - Hematology Oncology
100 North Mario Capecchi Drive, Suite 1400, Salt Lake City, UT 84113
Other Locations
Primary Children's Medical Center
100 North Mario Capecchi Drive, Medical Imaging, Salt Lake City, UT 84113
University of Utah Pediatric Rehab Clinic - St George
1380 East Medical Center Drive, Saint George, UT 84790

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease
A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease
Enrollment Status: Recruiting
Publish Date: April 30, 2025
Intervention Type: Biological
Study Drugs: Von Willebrand Factor, Factor VIII
Study Phase: Phase 3
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Biological
Study Drugs: PEG-Factor VIII, Eloctate ITI
Study Phase: Phase 3
View 1 Less Clinical Trial

22 Total Publications

Identification of two novel non-coding variants in Diamond-Blackfan Anemia Syndrome patients by whole genome sequencing.
Identification of two novel non-coding variants in Diamond-Blackfan Anemia Syndrome patients by whole genome sequencing.
Journal: Blood advances
Published: November 22, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Meznarich's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile